NCI-MATCH Precision Medicine Cancer Trial Opens

NCI-MATCH Precision Medicine Cancer Trial Opens

NCI-MATCH, the largest, most scientifically rigorous precision medicine trial in cancer to date, is now opening at cancer centers and community hospitals across the country.

The trial, also known as trial EAY131, seeks to determine whether matching certain drugs or drug combinations to people whose tumors have specific gene abnormalities will effectively treat their cancer, regardless of their cancer type. Treatment for this trial focuses on molecular abnormalities of a patient’s tumor instead of the organ site of the cancer.

The NCI-MATCH trial:

  • Seeks to enroll adults 18 years of age and older with any type of solid tumor or lymphoma (cancer in the cells of the immune system) that has returned or worsened after standard systemic therapy (oral or intravenous). Patients may also be eligible if they have a rare type of cancer for which there is no standard treatment.
  • Is a nationwide trial that is locally available and will enroll patients on a rolling basis as additional sites and treatment options become available (the trial opened with ten treatment arms and an additional 12 will be added within the next several months).
  • Requires patients to have a new biopsy and their tumor cells will need to undergo genetic testing to see if they contain one of the gene mutations being studied. If so, they will receive additional evaluation to determine if they meet the specific eligibility requirements of the treatment arms to be accepted in the trial. Trial researchers expect that about 1000 patients—one third of those screened—will have one or more molecular abnormalities that match one of the 22 treatment options being studied

NCI-MATCH was co-developed by the National Cancer Institute (NCI) and the ECOG-ACRIN Cancer Research Group, one of five NCI-sponsored National Clinical Trial Network Groups. ECOG-ACRIN is leading the trial.

For more information or to locate trial sites, contact the NCI Cancer Information Service at 1-800-4-CANCER or visit the NCI-MATCH page on Cancer.gov.